{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:00:22Z","timestamp":1761490822040,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.critrevonc.2019.07.017","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T19:09:53Z","timestamp":1564427393000},"page":"164-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"Ronald","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolph M.","family":"Navari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.07.017_bib0005","first-page":"2381","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis","volume":"24","author":"Chiu","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0010","first-page":"1001","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies : a systematic review","volume":"24","author":"Chow","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0015","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"NEJM"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy : a double-blind, double-dummy, randomized, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003495-200060030-00002","article-title":"Potential of substance P antagonists as anti-emetics","volume":"60","author":"Diemunsch","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0030","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.07.017_bib0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.21037\/apm.2018.03.09","article-title":"Efficacy of the combination of neurokinin-1 receptor antagonist, palonosetron and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Chow","year":"2018","journal-title":"Ann. Palliat. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.07.017_bib0040","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0045","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0050","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"17","author":"Aapro","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0055","first-page":"161","article-title":"A multicenter, double-blind randomized control clinical trial of palonosetron hydrochloride injection to prevent chemotherapy-induced nausea and vomiting","volume":"12","author":"Chen","year":"2007","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0060","first-page":"487","article-title":"Phase II trial of hydrochloride in the prevention of moderately to severely emetogenic chemotherapy induced nausea and vomiting","volume":"14","author":"Li","year":"2009","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0065","first-page":"99","article-title":"The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multi-center, randomized, double-blind, parallel, comparative clinical trial","volume":"17","author":"Yu","year":"2009","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2019.07.017_bib0070","first-page":"142","article-title":"Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting","volume":"2","author":"Ghosh","year":"2010","journal-title":"Int. J. Collab. Res. Int. Med. Pub. Health"},{"issue":"11","key":"10.1016\/j.critrevonc.2019.07.017_bib0075","first-page":"871","article-title":") clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer","volume":"51","author":"Kaushal","year":"2010","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0080","first-page":"1425","article-title":"Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients","volume":"28","author":"Dong","year":"2011","journal-title":"Med. Only"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0085","first-page":"2519","article-title":"Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis","volume":"26","author":"Chow","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0090","first-page":"1685","article-title":"Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Popovic","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0095","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiation-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann. Oncol."},{"issue":"28","key":"10.1016\/j.critrevonc.2019.07.017_bib0100","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN guidelines insights: antiemesis, version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J. Natl. Compre Cancer Netw."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12032-009-9398-2","article-title":"Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population","volume":"28","author":"Tian","year":"2011","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0115","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3892\/etm.2013.996","article-title":"The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting","volume":"5","author":"Huang","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0120","first-page":"S272","article-title":"The efficacy of palonosetron compared with granisetron in preventing chemotherapy-induced nausea and vomiting: a randomized study","volume":"49","author":"Kilickap","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2019.07.017_bib0125","first-page":"2845","article-title":"Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy","volume":"21","author":"Wenzell","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0130","first-page":"723","volume":"23","author":"Raftopoulos","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.07.017_bib0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3802\/jgo.2015.26.4.311","article-title":"Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer","volume":"26","author":"Fujiwara","year":"2015","journal-title":". J. Gynceol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer","volume":"9","author":"Kaushal","year":"2015","journal-title":"ecancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2019.07.017_bib0145","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cam4.373","volume":"4","author":"Kimura","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0150","first-page":"33","article-title":"Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen","author":"Matsumoto","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ol.2014.2640","article-title":"Comparison between antiemetic effects of palonosetron and granisetron in breast cancer patients with anthracycline-based regimens","volume":"9","author":"Ohzawa","year":"2015","journal-title":"Oncol. Lett."},{"issue":"489","key":"10.1016\/j.critrevonc.2019.07.017_bib0160","article-title":"Randomised comparison of palonosetron and ondansetron both combined with dexamethasone in prevention of emesis in lymphoma patients receiving moderately emetogenic regimen bendamustine and rituximab","volume":"101","author":"Ptushkin","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.07.017_bib0165","first-page":"945","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"24","author":"Seol","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.07.017_bib0170","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2019.07.017_bib0175","first-page":"S87","article-title":"Trial of antiemetic triplet therapy comparing palonosetron and granisetron in breast cancer patients receiving AC chemotherapy: double blind randomized comparative phase III study","volume":"24","author":"Tsuneizumi","year":"2016","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.07.017_bib0180","first-page":"4108","article-title":"Therapeutic effects of palonosetron plus tropisetron on chemotherapy-induced nausea and vomiting","volume":"11","author":"Liu","year":"2018","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819301611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:32:44Z","timestamp":1760902364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819301611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":36,"alternative-id":["S1040842819301611"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.017","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}